HK1199892A1 - Modified mini-hepcidin peptides and methods of using thereof - Google Patents
Modified mini-hepcidin peptides and methods of using thereofInfo
- Publication number
- HK1199892A1 HK1199892A1 HK15100404.3A HK15100404A HK1199892A1 HK 1199892 A1 HK1199892 A1 HK 1199892A1 HK 15100404 A HK15100404 A HK 15100404A HK 1199892 A1 HK1199892 A1 HK 1199892A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- modified mini
- hepcidin peptides
- hepcidin
- peptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161568724P | 2011-12-09 | 2011-12-09 | |
PCT/US2012/068180 WO2013086143A1 (fr) | 2011-12-09 | 2012-12-06 | Peptides mini-hepcidine modifiés et leurs procédés d'utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1199892A1 true HK1199892A1 (en) | 2015-07-24 |
Family
ID=48574865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15100404.3A HK1199892A1 (en) | 2011-12-09 | 2015-01-14 | Modified mini-hepcidin peptides and methods of using thereof |
Country Status (11)
Country | Link |
---|---|
US (2) | US9328140B2 (fr) |
EP (1) | EP2788370B1 (fr) |
JP (2) | JP6571333B2 (fr) |
CN (1) | CN104011066A (fr) |
AU (1) | AU2012327226C1 (fr) |
BR (1) | BR112014013697A2 (fr) |
CA (1) | CA2855122A1 (fr) |
HK (1) | HK1199892A1 (fr) |
IL (1) | IL232927A0 (fr) |
WO (1) | WO2013086143A1 (fr) |
ZA (1) | ZA201404962B (fr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4944360B2 (ja) | 2001-05-25 | 2012-05-30 | アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル(アンセルム) | 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用 |
US9328140B2 (en) | 2008-12-05 | 2016-05-03 | The Regents Of The University Of California | Modified mini-hepcidin peptides and methods of using thereof |
US8435941B2 (en) * | 2008-12-05 | 2013-05-07 | The Regents Of The University Of California | Mini-hepcidin peptides and methods of using thereof |
US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
EP4091624A1 (fr) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Analogues d'hepcidine et leurs utilisations |
US9981012B2 (en) | 2013-09-20 | 2018-05-29 | University Of Virginia Patent Foundation | Compositions and methods for protecting the kidney from ischemia reperfusion injury |
US10155798B2 (en) * | 2013-12-20 | 2018-12-18 | The Regents Of The University Of California | Anti-obesity compounds derived from neuromedin U |
CN106456703A (zh) * | 2014-04-07 | 2017-02-22 | 摩坚瑟生物技术股份有限公司 | 铁调素模拟肽及其用途 |
DK3143037T3 (da) | 2014-05-16 | 2021-09-20 | Protagonist Therapeutics Inc | Alpha4beta7-integrin-thioether-peptidantagonister |
CA2953721A1 (fr) * | 2014-06-27 | 2015-12-30 | Protagonist Therapeutics, Inc. | Analogues d'hepcidine et de mini-hepcidine, et leurs utilisations |
RU2736637C9 (ru) | 2014-07-17 | 2021-02-08 | Протагонист Терепьютикс, Инк. | Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника |
JP2017535527A (ja) | 2014-10-01 | 2017-11-30 | プロタゴニスト セラピューティクス, インコーポレイテッド | 新規のα4β7ペプチド単量体及び二量体拮抗薬 |
WO2016054445A1 (fr) | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | Nouveaux peptides monomères et dimères cycliques possédant une activité antagoniste de l'intégrine |
JP2018508466A (ja) * | 2014-12-29 | 2018-03-29 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | S−アルキル化ヘプシジンペプチドならびにその作製及び使用方法 |
US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
NZ740675A (en) | 2015-10-23 | 2024-02-23 | Vifor Int Ag | Novel ferroportin inhibitors |
CA3009834A1 (fr) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues de mimetiques d'hepcidine a demi-vie in vivo amelioree |
MX2018008299A (es) * | 2016-01-08 | 2018-09-21 | La Jolla Pharma Co | Metodos para administrar hepcidina. |
US10407468B2 (en) | 2016-03-23 | 2019-09-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing α4β7 peptide antagonists |
EP3509621A4 (fr) * | 2016-09-06 | 2020-06-17 | La Jolla Pharmaceutical Company | Méthodes de traitement d'une surcharge en fer |
WO2018107241A1 (fr) * | 2016-12-16 | 2018-06-21 | The University Of Sydney | Traitement de troubles en lien avec le fer |
MX2019007236A (es) * | 2016-12-19 | 2019-09-06 | La Jolla Pharma Co | Metodos de administracion de hepcidina. |
WO2018128828A1 (fr) | 2016-12-23 | 2018-07-12 | Bayer Healthcare Llc | Nouveaux mimétiques d'hepcidine et leurs utilisations |
JOP20180036A1 (ar) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
CA3073806A1 (fr) | 2017-09-11 | 2019-03-14 | Protagonist Therapeutics, Inc. | Peptides d'agoniste opioide et leurs utilisations |
WO2019157268A1 (fr) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Mimétiques d'hepcidine conjugués |
EP3894416B1 (fr) | 2018-12-13 | 2022-11-09 | Global Blood Therapeutics, Inc. | Inhibiteurs de ferroportine et procédés d'utilisation |
TW202102478A (zh) | 2019-04-01 | 2021-01-16 | 瑞士商威佛(國際)股份有限公司 | 新穎的鐵螯合物 |
EP3997105A4 (fr) | 2019-07-10 | 2023-09-13 | Protagonist Therapeutics, Inc. | Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires |
CN118005737A (zh) | 2020-01-15 | 2024-05-10 | 詹森生物科技公司 | 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途 |
WO2021222359A1 (fr) | 2020-04-28 | 2021-11-04 | Global Blood Therapeutics, Inc. | Thiénopyrimidines servant d'inhibiteurs de la ferroportine |
EP4143178A1 (fr) | 2020-04-28 | 2023-03-08 | Global Blood Therapeutics, Inc. | Pyrimidines cycloalkyliques utilisées en tant qu'inhibiteurs de la ferroportine |
CA3181583A1 (fr) | 2020-04-28 | 2021-11-04 | Global Blood Therapeutics, Inc. | Methodes d'utilisation de pyrimidines en tant qu'inhibiteurs de la ferroportine |
CA3202226A1 (fr) | 2020-11-20 | 2022-05-27 | Janssen Pharmaceutica Nv | Compositions d'inhibiteurs peptidiques du recepteur de l'interleukine-23 |
US20230310658A1 (en) * | 2022-03-30 | 2023-10-05 | Christopher Key | Compositions and methods for treating inflammatory disease |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUT44794A (en) * | 1985-12-04 | 1988-04-28 | Sandoz Ag | Process for production of calcitonine-derivatives and medical preparatives containing such compounds |
AU2004231122B2 (en) | 2003-04-15 | 2010-04-08 | Xenon Pharmaceuticals Inc. | Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof |
US7723063B2 (en) | 2004-04-28 | 2010-05-25 | Intrinsic Lifesciences | Methods for measuring levels of bioactive human hepcidin |
US7534764B2 (en) | 2005-06-29 | 2009-05-19 | The Regents Of The University Of California | Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin |
JP2010517529A (ja) * | 2007-02-02 | 2010-05-27 | アムジエン・インコーポレーテツド | ヘプシジン及びヘプシジン抗体 |
US8435941B2 (en) * | 2008-12-05 | 2013-05-07 | The Regents Of The University Of California | Mini-hepcidin peptides and methods of using thereof |
US9328140B2 (en) | 2008-12-05 | 2016-05-03 | The Regents Of The University Of California | Modified mini-hepcidin peptides and methods of using thereof |
EP4091624A1 (fr) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Analogues d'hepcidine et leurs utilisations |
-
2012
- 2012-12-06 US US14/363,012 patent/US9328140B2/en not_active Expired - Fee Related
- 2012-12-06 WO PCT/US2012/068180 patent/WO2013086143A1/fr active Application Filing
- 2012-12-06 BR BR112014013697-1A patent/BR112014013697A2/pt not_active Application Discontinuation
- 2012-12-06 EP EP12856566.0A patent/EP2788370B1/fr active Active
- 2012-12-06 AU AU2012327226A patent/AU2012327226C1/en not_active Ceased
- 2012-12-06 CA CA2855122A patent/CA2855122A1/fr not_active Abandoned
- 2012-12-06 JP JP2014546062A patent/JP6571333B2/ja not_active Expired - Fee Related
- 2012-12-06 CN CN201280064227.1A patent/CN104011066A/zh active Pending
-
2014
- 2014-06-02 IL IL232927A patent/IL232927A0/en unknown
- 2014-07-07 ZA ZA2014/04962A patent/ZA201404962B/en unknown
-
2015
- 2015-01-14 HK HK15100404.3A patent/HK1199892A1/xx unknown
-
2016
- 2016-03-28 US US15/082,158 patent/US9896481B2/en active Active
-
2018
- 2018-02-01 JP JP2018016145A patent/JP2018087215A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2788370B1 (fr) | 2020-02-05 |
US9896481B2 (en) | 2018-02-20 |
AU2012327226C9 (en) | 2017-02-16 |
EP2788370A1 (fr) | 2014-10-15 |
JP2018087215A (ja) | 2018-06-07 |
US9328140B2 (en) | 2016-05-03 |
BR112014013697A2 (pt) | 2020-11-03 |
EP2788370A4 (fr) | 2015-07-08 |
AU2012327226C1 (en) | 2017-03-02 |
AU2012327226B2 (en) | 2016-04-14 |
JP6571333B2 (ja) | 2019-09-04 |
CA2855122A1 (fr) | 2013-06-13 |
IL232927A0 (en) | 2014-07-31 |
US20160200765A1 (en) | 2016-07-14 |
ZA201404962B (en) | 2019-04-24 |
US20140336110A1 (en) | 2014-11-13 |
WO2013086143A1 (fr) | 2013-06-13 |
CN104011066A (zh) | 2014-08-27 |
JP2015504859A (ja) | 2015-02-16 |
AU2012327226A1 (en) | 2013-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1199892A1 (en) | Modified mini-hepcidin peptides and methods of using thereof | |
HK1255608A1 (zh) | 抗htra1抗體及使用方法 | |
HK1223550A1 (zh) | 芳香族陽離子肽及其用途 | |
HK1212256A1 (en) | Anti-mcam antibodies and associated methods of use -mcam | |
EP2721063A4 (fr) | Polypeptides liant pcsk9 et leurs procédés d'utilisation | |
HK1244540A1 (zh) | 芳香族陽離子肽及其用途 | |
IL230918A0 (en) | Modified proteins and peptides | |
HK1197028A1 (en) | Aromatic-cationic peptides and uses of same | |
ZA201403760B (en) | Anti-cd98 antibodies and methods of use thereof | |
HK1201843A1 (en) | Anti-polyubiquitin antibodies and methods of use | |
EP2782589A4 (fr) | Peptides antimicrobiens et procédés d'utilisation de ces derniers | |
HK1201443A1 (en) | Aromatic-cationic peptides and uses of same | |
HK1203161A1 (en) | Peptides and methods of using same | |
ZA201400562B (en) | Axmi205 variant proteins and methods for their use | |
EP2738255A4 (fr) | Peptide issu de erap1 et son utilisation | |
EP2793921A4 (fr) | Peptides dérivés de saposine a et utilisations de ceux-ci | |
EP2670245A4 (fr) | Alpha-cétohétérocycles et leurs procédés de fabrication et d'utilisation | |
EP2762149A4 (fr) | Peptide dérivé de l'érythropoïétine et son utilisation | |
EP2771689A4 (fr) | Peptides usp2a et anticorps | |
GB201121226D0 (en) | Modified proteins and peptides | |
GB201121233D0 (en) | Modified proteins and peptides | |
GB201121236D0 (en) | Proteins and peptides |